Skip to main content
  • Subthalamic Local Field Potentials in Parkinson’s Disease and Isolated Dystonia: An Evaluation of Potential Biomarkers

    Final Number:

    Doris D Wang MD, PhD; Coralie de Hemptinne PhD; Svjetlana Miocinovic MD, PhD; Jill L. Ostrem MD; Philip A. Starr MD, PhD

    Study Design:
    Laboratory Investigation

    Subject Category:
    Movement Disorders

    Meeting: 2016 ASSFN Biennial Meeting

    Introduction: Local field potentials (LFP) recorded from the subthalamic nucleus in patients with Parkinson’s disease (PD) demonstrate prominent oscillations in the beta (13-30 Hz) frequency range, and reduction of beta band spectral power by levodopa and deep brain stimulation (DBS) is correlated with motor symptom improvement. Several features of beta activity have been theorized to be specific biomarkers of the parkinsonian state, though these have rarely been studied in non-parkinsonian conditions.

    Methods: To compare resting state LFP features in PD and isolated dystonia and evaluate disease-specific biomarkers, we recorded subthalamic LFPs from 28 akinetic-rigid PD and 12 isolated dystonia patients during awake DBS implantation. Spectral power and phase-amplitude coupling characteristics were analyzed.

    Results: In 26/28 PD and 11/12 isolated dystonia patients, the LFP power spectrum had a peak in the beta frequency range, with similar amplitudes between groups. Resting state power did not differ between groups in the theta (5-8 Hz), alpha (8-12 Hz), beta (13-30 Hz), broadband gamma (50-200 Hz), or high frequency oscillation (HFO, 250-350 Hz) bands. Analysis of phase-amplitude coupling between low frequency phase and HFO amplitude revealed significant interactions in 19/28 PD and 6/12 dystonia recordings without significant differences in maximal coupling or preferred phase.

    Conclusions: Two features of subthalamic LFPs that have been proposed as specific parkinsonian biomarkers, beta power and coupling of beta phase to HFO amplitude, were also present in isolated dystonia, including focal dystonias. This casts doubt on the utility of these metrics as disease-specific diagnostic biomarkers.

    Patient Care: Understanding the pathophysiology of basal ganglia disease can help improve DBS therapy by designing closed-loop stimulation paradigms

    Learning Objectives: STN LFP in PD and dystonia both show prominent beta oscillations STN LFP beta power does not appear to be a specific biomarker for PD PD and dystonia show significant interaction between beta phase and high frequency gamma amplitude


We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy